Retifanlimab gets knocked back by a US adcom. Could a rival now beat it to become the eighth anti-PD-(L)1 to reach the US market?
PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.
Here's a round up of Vantage's coverage of the 2020 European Society for Medical Oncology congress.
A benefit for balstilimab in cervical cancer irrespective of PD-L1 expression gives Agenus a shot at US approval.
The upcoming virtual Esmo congress gives top billing to big pharma immunotherapies.
A Vantage analysis suggests which small biotechs might seriously have to rethink R&D spending plans in the wake of Covid-19.